AN AUDIT TO DETERMINE THE SAFETY OF THE NOVEL ORAL ANTICOAGULANTS, DABIGATRAN AND RIVAROXABAN, FOR PATIENTS INITIATED ON ANTICOAGULANT THERAPY

被引：0
|
作者：
Kurunadalingam, H. [1 ]
Vizcaychipi, M. P. [1 ]
Patel, S. [1 ]
Gabriel, I. H. [2 ]
Yarranton, H. [2 ]
Morgan, D. J. Richard [3 ]
机构：
[1] Chelsea & Westminster Hosp, Anaesthesia, London, England
[2] Chelsea & Westminster Hosp, Med, London, England
[3] Chelsea & Westminster Hosp, Med & Emergency Dept Directorate, London, England
来源：
ANESTHESIA AND ANALGESIA | 2014年 / 118卷
关键词：
D O I：
暂无
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
S-216
引用
收藏
页码：S216 / S216
页数：1
相关论文
共 50 条
  • [41] HOSPITAL READMISSIONS AMONG PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION TREATED WITH THE NEW ORAL ANTICOAGULANTS, APIXABAN, DABIGATRAN, AND RIVAROXABAN
    Deitelzweig, Steven
    Gupta, Kiran
    Nadkarni, Anagha
    Trocio, Jeffrey
    Lin, Jay
    Lingohr-Smith, Melissa
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 805 - 805
  • [42] A novel oral anticoagulant, dabigatran, in acute renal infarction
    Altin, Cihan
    Sakallioglu, Onur
    Gezmis, Esin
    Muderrisoglu, Haldun
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2015, 15 (02): : 158 - 159
  • [43] An Update on the "Novel" and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
    Djulbegovic, Mia
    Lee, Alfred Ian
    CLINICS IN CHEST MEDICINE, 2018, 39 (03) : 583 - +
  • [44] PHARMACOKINETICS (PK) OF EDOXABAN, A NOVEL ORAL ANTICOAGULANT (NOAC), WHEN DOSED ALONE OR FOLLOWING SWITCHING FROM DABIGATRAN OR RIVAROXABAN
    Parasrampuria, D.
    Weilert, D.
    Maa, J.
    He, L.
    Shi, M.
    Brown, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S83 - S83
  • [45] Anticoagulant therapy during perioperative treatment in patients treated with oral anticoagulants - bridging therapy
    Urbanek, Tomasz
    ACTA ANGIOLOGICA, 2008, 14 (04): : 111 - 124
  • [46] An audit of the use of novel anticoagulants: Dabiagtran and Rivaroxaban for stroke prevention in AF
    Rhodes, S.
    Bond, S. K.
    Bailey, J.
    Curtis, K.
    McMullon, A.
    Mowbray, M.
    Percival, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 84 - 84
  • [47] Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
    Ulehlova, Jana
    Pisklakova, Barbora
    Ivanovova, Eliska
    Prochazkova, Jana
    Bradacova, Pavla
    Kvasnicka, Ales
    Friedecky, David
    Slavik, Ludek
    DIAGNOSTICS, 2021, 11 (11)
  • [48] Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban
    Lin, Yu-Sheng
    Kuan, Feng-Che
    Chao, Tze-Fan
    Wu, Michael
    Chen, Shao-Wei
    Chen, Mien-Cheng
    Chung, Chang-Ming
    Chu, Pao-Hsien
    Lip, Gregory Y. H.
    Wu, Victor Chien-Chia
    CANCER MEDICINE, 2021, 10 (20): : 7079 - 7088
  • [49] Outpatient DVT treatment - an audit of safety indicators for patients on oral anticoagulant treatment
    Bacon, S.
    Chadwick, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1093 - 1093
  • [50] Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation
    Huybrechts, Krista F.
    Gopalakrishnan, Chandrasekar
    Bartels, Dorothee B.
    Zint, Kristina
    Gurusamy, Venkatesh K.
    Landon, Joan
    Schneeweiss, Sebastian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (06) : 1405 - 1419
12345